These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36779261)

  • 1. The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths.
    Karami S; Ajao A; Wong J; Zhang D; Meyer T; Ding Y; Secora A; Major JM; Gill R; Chai GP; Zhao Y; McAninch J
    Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):735-751. PubMed ID: 36779261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of more restrictive hydrocodone rescheduling on unintentional pediatric opioid exposures.
    Mallama C; Karami S; Zhang D; Zhao Y; Yang Y; Woods C; Ding Y; Meyer T; McAninch J
    Pharmacoepidemiol Drug Saf; 2024 Jun; 33(6):e5793. PubMed ID: 38783553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling.
    Wu A; Phan C; Nguyen KC; Quindoy M; Lewis J; Apollonio DE
    Clin Toxicol (Phila); 2021 Apr; 59(4):313-319. PubMed ID: 32840386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Hydrocodone Misuse Exposures Reported to U.S. Poison Centers Following Rescheduling in 2014.
    Fischer LJ; Severtson SG; Gurrola MC; Iwanicki JL; Green JL; Dart RC
    Subst Use Misuse; 2022; 57(7):1097-1103. PubMed ID: 35450512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of opioid prescribing after rescheduling of hydrocodone-containing products.
    Bernhardt MB; Taylor RS; Hagan JL; Patel N; Chumpitazi CE; Fox KA; Glover C
    Am J Health Syst Pharm; 2017 Dec; 74(24):2046-2053. PubMed ID: 29222361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
    Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone.
    Haynes A; Kleinschmidt K; Forrester MB; Young A
    Clin Toxicol (Phila); 2016 Jun; 54(5):434-40. PubMed ID: 26919555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Increased Hydrocodone Regulation on Opioid Prescribing in an Urban Safety-Net Health Care System.
    Northrup TF; Carroll K; Suchting R; Villarreal YR; Zare M; Stotts AL
    J Am Board Fam Med; 2019; 32(3):362-374. PubMed ID: 31068400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Hydrocodone Rescheduling on Dental Prescribing of Opioids.
    Yan CH; Hubbard CC; Lee TA; Sharp LK; Evans CT; Calip GS; Rowan SA; McGregor JC; Gellad WF; Suda KJ
    JDR Clin Trans Res; 2023 Oct; 8(4):402-412. PubMed ID: 35708454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review.
    Usmani SA; Hollmann J; Goodin A; Hincapie-Castillo JM; Adkins LE; Ourhaan N; Oueini R; Bhagwandass H; Easey T; Vouri SM
    J Am Pharm Assoc (2003); 2021; 61(2):e20-e44. PubMed ID: 33127312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Online Conversation Monitoring to Understand the Opioid Epidemic: Epidemiological Surveillance Study.
    Black JC; Margolin ZR; Olson RA; Dart RC
    JMIR Public Health Surveill; 2020 Jun; 6(2):e17073. PubMed ID: 32597786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Rescheduling Hydrocodone on Opioid Prescribing in Ohio.
    Liu Y; Baker O; Schuur JD; Weiner SG
    Pain Med; 2020 Sep; 21(9):1863-1870. PubMed ID: 31502638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Enforcement Administration Rescheduling of Hydrocodone Combination Products Is Associated With Changes in Physician Pain Management Prescribing Preferences.
    Fleming ML; Driver L; Sansgiry SS; Abughosh SM; Wanat MA; Varisco TJ; Pickard T; Reeve K; Todd KH
    J Pain Palliat Care Pharmacother; 2019; 33(1-2):22-31. PubMed ID: 31454279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a potential opioid misuse measure from administrative dispensing data and contrasting opioid misuse among individuals on long-term tramadol, long-term short-acting hydrocodone or long-term short-acting oxycodone therapy in Arkansas.
    Acharya M; Hayes CJ; Li C; Painter JT; Dayer L; Martin BC
    Curr Med Res Opin; 2022 Nov; 38(11):1947-1957. PubMed ID: 36000252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011.
    Atluri S; Sudarshan G; Manchikanti L
    Pain Physician; 2014; 17(2):E119-28. PubMed ID: 24658483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Race and ethnicity: Not factors in the prescribing of hydrocodone and codeine-containing products in two pediatric emergency departments.
    Rees CA; Bernhardt MB; Camp EA; Lin JS; Chumpitazi CE
    J Opioid Manag; 2019; 15(3):229-233. PubMed ID: 31343724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.
    Fleming ML; Driver L; Sansgiry SS; Abughosh SM; Wanat M; Sawant RV; Ferries E; Reeve K; Todd KH
    Res Social Adm Pharm; 2017; 13(3):503-512. PubMed ID: 27567741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.
    Tran S; Lavitas P; Stevens K; Greenwood BC; Clements K; Alper CJ; Lenz K; Price M; Hydery T; Arnold JL; Takeshita M; Bacon R; Peristere JP; Jeffrey PL
    J Manag Care Spec Pharm; 2017 May; 23(5):532-539. PubMed ID: 28448772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased Opioid Prescribing in a Pediatric Emergency Department After the Rescheduling of Hydrocodone.
    Chumpitazi CE; Rees CA; Camp EA; Bernhardt MB
    J Emerg Med; 2017 Apr; 52(4):547-553. PubMed ID: 27727038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.